Ubs Group Ag Bluebird Bio, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 99,105 shares of BLUE stock, worth $29,731. This represents 0.0% of its overall portfolio holdings.

Number of Shares

99,105

Previous 68,568 44.54%

Holding current value

$29,731

Previous $67,000 23.88%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.47 - $1.35 $14,352 - $41,224	30,537 Added 44.54%	99,105 $51,000
Q2 2024 Aug 13, 2024	SELL	$0.85 - $1.26 $127,973 - $189,701	-150,557 Reduced 68.71%	68,568 $67,000
Q1 2024 May 13, 2024	SELL	$0.91 - $1.75 $424,258 - $815,881	-466,218 Reduced 68.03%	219,125 $280,000
Q4 2023 Feb 09, 2024	BUY	$1.32 - $4.83 $524,664 - $1.92 Million	397,473 Added 138.07%	685,343 $945,000
Q3 2023 Nov 09, 2023	SELL	$3.02 - $4.05 $396,577 - $531,833	-131,317 Reduced 31.33%	287,870 $875,000
Q2 2023 Aug 11, 2023	SELL	$2.79 - $5.03 $355,607 - $641,113	-127,458 Reduced 23.32%	419,187 $1.38 Million
Q1 2023 May 12, 2023	SELL	$3.14 - $8.22 $423,799 - $1.11 Million	-134,968 Reduced 19.8%	546,645 $1.74 Million
Q4 2022 Feb 08, 2023	BUY	$5.77 - $8.49 $3.13 Million - $4.61 Million	543,264 Added 392.68%	681,613 $4.72 Million
Q3 2022 Nov 10, 2022	BUY	$3.75 - $7.39 $508,305 - $1 Million	135,548 Added 4839.27%	138,349 $877,000
Q2 2022 Aug 10, 2022	SELL	$2.94 - $5.23 $2.4 Million - $4.28 Million	-817,649 Reduced 99.66%	2,801 $12,000
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $1.73 Million - $4.51 Million	425,037 Added 107.49%	820,450 $3.98 Million
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $1.84 Million - $3.35 Million	205,602 Added 108.32%	395,413 $3.95 Million
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $1.99 Million - $3.71 Million	176,868 Added 1366.51%	189,811 $3.63 Million
Q2 2021 Aug 13, 2021	SELL	$18.04 - $22.09 $1.05 Million - $1.28 Million	-58,074 Reduced 81.77%	12,943 $413,000
Q1 2021 May 12, 2021	BUY	$16.59 - $33.89 $706,866 - $1.44 Million	42,608 Added 149.98%	71,017 $2.14 Million
Q4 2020 Feb 11, 2021	SELL	$27.5 - $37.92 $211,805 - $292,059	-7,702 Reduced 21.33%	28,409 $1.23 Million
Q3 2020 Nov 12, 2020	BUY	$34.44 - $43.75 $68,914 - $87,543	2,001 Added 5.87%	36,111 $1.95 Million
Q2 2020 Jul 31, 2020	BUY	$27.12 - $45.97 $283,566 - $480,662	10,456 Added 44.2%	34,110 $2.08 Million
Q1 2020 May 01, 2020	BUY	$26.16 - $63.5 $195,415 - $474,345	7,470 Added 46.16%	23,654 $1.09 Million
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $2.67 Million - $3.51 Million	-56,861 Reduced 77.84%	16,184 $1.42 Million
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $1.91 Million - $3 Million	32,175 Added 78.73%	73,045 $6.71 Million
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $104,431 - $144,874	-1,377 Reduced 3.26%	40,870 $5.2 Million
Q1 2019 May 14, 2019	SELL	$64.44 - $104.11 $3.22 Million - $5.2 Million	-49,991 Reduced 54.2%	42,247 $6.65 Million
Q4 2018 Feb 14, 2019	BUY	$59.1 - $93.26 $2.93 Million - $4.63 Million	49,609 Added 116.37%	92,238 $9.15 Million
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $989,367 - $1.31 Million	-11,134 Reduced 20.71%	42,629 $6.22 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $62,673 - $80,254	629 Added 1.18%	53,763 $8.44 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $2.19 Million - $3.13 Million	20,723 Added 63.94%	53,134 $9.07 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $1.63 Million - $2.62 Million	-20,016 Reduced 38.18%	32,411 $5.77 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $1.38 Million - $2.19 Million	23,935 Added 84.01%	52,427 $7.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	22,393 Added 367.16%	28,492 $2.99 Million
Q1 2017 Nov 14, 2017	BUY	N/A	6,099	6,099 $554,000

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $23.1M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account